Latest news with #LAVA
Yahoo
23-04-2025
- Entertainment
- Yahoo
Off the Grid: Sally breaks down USA TODAY's daily crossword puzzle, Jam-packed
There are spoilers ahead. You might want to solve today's puzzle before reading further! Jam-packed Constructor: Sala Wanetick Editor: Amanda Rafkin ANI (11D: Mikey's "Anora" character) The 2024 movie Anora won the Palme d'Or at the Cannes Film Festival. Mikey Madison stars as the title character, Anora "ANI" Mikheeva, a stripper who lives in Brighton Beach, a Russian American neighborhood in Brooklyn. Mikey Madison won an Academy Award for Best Actress for the role. AOC (17A: Rep. from the Bronx) Alexandria Oasis-Cortez represents New York's 14th congressional district in the U.S. House of Representatives. The abbreviation of representative (rep.) in the clue alerts solvers that the answer will be an abbreviation. ERIE (24A: Cedar Point's county and lake) Cedar Point is an amusement park in Sandusky, Ohio, which is in ERIE County. The park is located on a peninsula that extends into Lake ERIE. This is the second appearance this month for our crossword friend ERIE. ELLA (29A: Singer-songwriter ___ Mai) In 2019, ELLA Mai won the Billboard Music Award for Top R&B Artist. Her first U.S. top ten hit was "Boo'd Up," released in 2017. ELLA Mai's most recent single, "Little Things," was released in 2024. LAVA (42A: Stuff in a '90s lamp) LAVA lamps, with their bobbing and floating globs of wax (it's not actually LAVA in the lamp, of course...), have been around since 1963. LAVA lamps experienced a surge of popularity in the '90s, partially due to their appearance in the Austin Powers movies. REN (55A: "Star Wars" villain Kylo) The Star Wars' villain Kylo REN was played by Adam Driver in The Force Awakens (2015), The Last Jedi (2017), Star Wars Resistance (2018-2020), and The Rise of Skywalker. Kylo REN is the chosen name of Ben Solo, the son of Princess Leia Organa Skywalker, and Han Solo. Kylo Ren was originally trained as a Jedi by Luke Skywalker (his uncle), but is persuaded to join the dark side (as his grandfather did). TAJIN (49A: Seasoning on the rim of a spicy margarita glass, perhaps) TAJÍN is a seasoning consisting mainly of chili peppers, lime, and salt. It is sold by a Mexican company founded in 1985. As the clue informs us, Tajín may be used on the rim of a spicy margarita glass instead of salt. SO COOL (3D: The cat's meow) Cartoonist Tad Dorgan (1877-1929) is credited with coining the term "the cat's meow" to refer to something that is "SO COOL." My cat, Willow, definitely consider's herself to be the cat's meow. MESSI (7D: World Cup star Lionel) Lionel MESSI is a professional soccer player for the Argentina national team and for the Major League Soccer (MLS) team Inter Miami. Lionel MESSI is considered one of the greatest soccer players of all time; he led Argentina to a 2022 FIFA World Cup win, the country's first World Cup win since 1986. ASIA (8D: India's continent) India is a country in South ASIA. The capital of India is New Delhi. This is the second appearance of our crossword friend ASIA this month. It's fun to see our crossword friends ASIA and ERIE in the same puzzle. Although it does happen occasionally, it's been a while since we've seen these two entries in the same puzzle; the last time was March 4, 2024. DAN (12D: "Schitt's Creek" actor Levy) Schitt's Creek is a TV series about the Rose family, a formerly wealthy family that relocates to a small town named Schitt's Creek, which they once purchased as a joke. DAN Levy co-created Schitt's Creek with his father, Eugene Levy. They both have roles in the show; Eugene Levy portrays Johnny Rose, and DAN Levy portrays his son, David Rose. We've seen this clue before. Sometimes the answer has been DAN, as it is today, and sometimes the answer has been Eugene. PEDRO (22D: "Gladiator II" actor Pascal) Gladiator II is a 2024 historical epic film, and – as one might guess – a sequel to the movie Gladiator, which was released in 2000. PEDRO Pascal portrays General Acacius, a general in the Roman army. UMA (35D: "Kill Bill" actress Thurman) In the Kill Bill movies (Kill Bill: Volume 1 (2003) and Kill Bill: Volume 2 (2004)), UMA Thurman stars as the Bride, a former member of the Deadly Viper Assassination Squad. KERMIT (48D: Miss Piggy's on-again-off-again partner) I'll always be happy to see a reference to KERMIT and Miss Piggy in the puzzle. DAMES (54D: Maggie Smith and Judi Dench) Back in January we saw DAMES clued as [Judi Dench and Maggie Smith, e.g.]. Today DAME Maggie Smith gets top billing. DAME Maggie Smith (1934-2024) and Judi Dench have had amazing stage and screen careers. A few other clues I especially enjoyed: ELDER (6D: Person who transmits cultural knowledge) SLEEP (40D: Result of counting sheep (hopefully)) ACRES (53D: Disneyland Park occupies over 100 of them) STORAGE SPACE (20A: What attics, basements or garages might provide) TICKLE MONSTER (37A: "Creature" trying to make you laugh) TAPIOCA PEARL (56A: Bubble tea morsel) JAM-PACKED: The last word of each theme answer can be paired with the word JAM to create a new phrase: SPACE JAM, MONSTER JAM, and PEARL JAM. I like that the newly-created phrases represent a variety of types of things. SPACE JAM is a 1996 movie. MONSTER JAM is an event featuring MONSTER trucks. Last but not least, PEARL JAM is a band. Thank you, Sala, for this enjoyable puzzle. USA TODAY's Daily Crossword Puzzles Sudoku & Crossword Puzzle Answers This article originally appeared on USA TODAY: Crossword Blog & Answers for April 23, 2025 by Sally Hoelscher
Associated Press
16-04-2025
- Business
- Associated Press
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
Exemption from the $5.1 million repayment obligation strengthens LAVA's balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, 'LAVA,' 'the Company'), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) granted a full waiver of the final payment obligation related to the Innovation Credit, in the amount of $5.1 million. 'As part of LAVA's ongoing strategic review, we have implemented a targeted cost optimization initiative to enhance operational efficiency and financial flexibility,' said Steve Hurly, Chief Executive Officer of LAVA. 'Securing the $5.1 million repayment waiver is a significant milestone in this effort. This waiver strengthens our balance sheet by eliminating this outstanding debt obligation. We are grateful for the opportunity to work with the RVO and be part of the Innovation Credit program.' The Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) Innovation Credit provides financing in the form of an interest-bearing loan to support the development of innovative programs according to defined criteria. LAVA was awarded a Netherlands Innovation Credit in 2019 related to the development of LAVA-051 and pledged certain assets of that project, including certain intellectual property (IP), as a guarantee. About LAVA Therapeutics LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell anti-tumor effector functions upon cross-linking to tumor-associated antigens. LAVA's pipeline includes three internal and partnered clinical-stage bispecific gamma-delta T cell engagers for the treatment of solid tumor and hematological cancers including LAVA 1266, targeting CD123+ cancers (ACTRN12624001214527); PF-08046052, targeting EGFR (NCT05983133); and JNJ-89853413, targeting hematological cancers (NCT06618001). The pipeline also includes preclinical programs. For more information on LAVA, please visit our website at or follow us on LinkedIn, X, and YouTube. Gammabody® is a registered trademark of LAVA Therapeutics N.V. LAVA's Cautionary Note on Forward-Looking StatementsCONTACTS Investor Relations [email protected] LifeSci Advisors (IR/Media) Joyce Allaire [email protected]
Yahoo
16-04-2025
- Business
- Yahoo
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
Exemption from the $5.1 million repayment obligation strengthens LAVA's balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, 'LAVA,' 'the Company'), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) granted a full waiver of the final payment obligation related to the Innovation Credit, in the amount of $5.1 million. 'As part of LAVA's ongoing strategic review, we have implemented a targeted cost optimization initiative to enhance operational efficiency and financial flexibility,' said Steve Hurly, Chief Executive Officer of LAVA. 'Securing the $5.1 million repayment waiver is a significant milestone in this effort. This waiver strengthens our balance sheet by eliminating this outstanding debt obligation. We are grateful for the opportunity to work with the RVO and be part of the Innovation Credit program.' The Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) Innovation Credit provides financing in the form of an interest-bearing loan to support the development of innovative programs according to defined criteria. LAVA was awarded a Netherlands Innovation Credit in 2019 related to the development of LAVA-051 and pledged certain assets of that project, including certain intellectual property (IP), as a guarantee. About LAVA Therapeutics LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell anti-tumor effector functions upon cross-linking to tumor-associated antigens. LAVA's pipeline includes three internal and partnered clinical-stage bispecific gamma-delta T cell engagers for the treatment of solid tumor and hematological cancers including LAVA 1266, targeting CD123+ cancers (ACTRN12624001214527); PF-08046052, targeting EGFR (NCT05983133); and JNJ-89853413, targeting hematological cancers (NCT06618001). The pipeline also includes preclinical programs. For more information on LAVA, please visit our website at or follow us on LinkedIn, X, and YouTube. Gammabody® is a registered trademark of LAVA Therapeutics N.V. LAVA's Cautionary Note on Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are 'forward-looking statements'. Words such as 'anticipate', 'believe', 'could', 'will', 'may', 'expect', 'should', 'plan', 'intend', 'estimate', 'potential', 'suggests', and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA's expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements relating to LAVA's initiatives to increase cost optimization and efficiencies. Many factors, risks and uncertainties may cause differences between current expectations and actual results, including, among other things, LAVA's ability to leverage its initial programs to develop additional product candidates using its Gammabody® platform, the failure of LAVA's collaborators to support or advance collaborations or LAVA's product candidates, the timing and results of LAVA's research and development programs and preclinical and clinical trials, the possibility that clinical trials may fail to establish sufficient efficacy, the risk that adverse events or safety signals may occur in clinical trials, the risk that results obtained in preclinical studies or clinical trials to date may not be indicative of results obtained in ongoing or future trials, the risk that adverse regulatory actions or other setbacks could occur in clinical trials even after promising results in earlier clinical trials or preclinical studies, LAVA's ability to obtain regulatory approval for and commercialize its product candidates, LAVA's ability to identify any strategic alternatives or if so identified, be able to consummate any such transactions on terms acceptable to LAVA and its shareholders, and the risk that setbacks in development could occur as a result of the difficulty and uncertainty of pharmaceutical product development and other factors. There may be adverse effects on LAVA's business condition and results from general economic and market conditions and overall fluctuations in the United States and international credit and financial markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities, including the conflict in Ukraine and the conflict in the Middle East. These and other risks are described in greater detail under the caption 'Risk Factors' in LAVA's most recent Annual Report on Form 10-K and other filings LAVA makes with the U.S. Securities and Exchange Commission. LAVA assumes no obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, change in expectations or otherwise, except as otherwise required by law. CONTACTSInvestor Relationsir@ LifeSci Advisors (IR/Media)Joyce AllaireJallaire@ in to access your portfolio
Yahoo
25-02-2025
- Business
- Yahoo
LAVA Announces Evaluation of Strategic Options
Advisor engaged in evaluating strategic options to maximize shareholder value Cash balance of $76.6 million as of December 31, 2024 UTRECHT, The Netherlands and PHILADELPHIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, 'LAVA,' 'the Company'), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced that the Company has initiated a process to review strategic options focused on maximizing shareholder value and has implemented cost curtailment including a workforce reduction. The Company has retained an experienced financial advisor to support LAVA with the strategic evaluation process. LAVA will continue to enroll in the Phase 1 clinical study evaluating the safety and pharmacokinetics of LAVA-1266 in hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and support its partnerships with Pfizer and Johnson and Johnson. 'While we will continue investigating LAVA-1266 in the potential treatment of AML and MDS and supporting our Gammabody pharma partnerships, with only one product in clinical development and an early-stage pipeline, we felt it appropriate to investigate strategic opportunities to drive additional shareholder value. LAVA is in a strong position to unlock strategic opportunities for the Company, in addition to our proprietary pipeline and partnered programs,' said Steve Hurly, Chief Executive Officer of LAVA. The Company will explore and evaluate diverse strategic options to maximize shareholder value, including in-licensing of assets, a sale, licensing agreement, merger, acquisition, or other strategic transactions. There can be no assurance that this process will result in any such transaction. LAVA's Board of Directors has not set a timetable for the strategic review process. LAVA does not intend to provide updates until the Board approves a specific action or otherwise determines that disclosure is appropriate or required. In connection with the evaluation of strategic alternatives, LAVA is implementing a restructuring plan that includes a workforce reduction of approximately thirty percent, furthering cost-containment and cash conservation measures. The Company intends to retain all employees essential for supporting value creation as part of its strategic review. The Company estimates that it will incur approximately $0.5 million of one-time costs primarily incurred in Q1 2025 related to the workforce reduction. 'I want to express my sincere gratitude to each of our employees being affected by this workforce reduction,' said Mr. Hurly. 'We thank them for their dedicated service and contribution to LAVA's mission to advancing the portfolio of bispecific T cell engagers and our proprietary Gammabody platform.' As of December 31, 2024, the Company's cash, cash equivalents, and investments were $76.6 million (unaudited). About LAVA Therapeutics LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell anti-tumor effector functions upon cross-linking to tumor-associated antigens. LAVA's pipeline includes three internal and partnered clinical-stage bispecific gamma-delta T cell engagers for the treatment of solid tumor and hematological cancers including LAVA 1266, targeting CD123+ cancers (ACTRN12624001214527); PF-08046052, targeting EGFR (NCT05983133); and JNJ-89853413, targeting hematological cancers (NCT06618001). The pipeline also includes preclinical programs. For more information on LAVA, please visit our website at or follow us on LinkedIn, X, and YouTube. Gammabody® is a registered trademark of LAVA Therapeutics N.V. LAVA's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipate', 'believe', 'could', 'will', 'may', 'expect', 'should', 'plan', 'intend', 'estimate', 'potential', 'suggests', and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA's expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include but are not limited to statements relating to LAVA's evaluation of strategic alternatives and transactions to maximize shareholder value, LAVA's ability to preserve capital and the sufficiency of cash on hand, the reduction in force in employees at the Company, as well as the therapeutic potential, development strategy and potential uses of LAVA's product candidates, including LAVA-1266, the timing of initiation of clinical trials and achievement of clinical milestones, LAVA's cash runway and the sufficiency of resources to pursue development activities, progress and data from clinical trials, and the ability of LAVA's product candidates to treat various tumor targets and improve patient outcomes, among others. Many factors, risks and uncertainties may cause differences between current expectations and actual results, including, among other things, the Company's ability to leverage its initial programs to develop additional product candidates using its Gammabody® platform, the failure of LAVA's collaborators to support or advance collaborations or LAVA's product candidates, the timing and results of LAVA's research and development programs and preclinical and clinical trials, the possibility that clinical trials may fail to establish sufficient efficacy, the risk that adverse events or safety signals may occur in clinical trials, the risk that results obtained in preclinical studies or clinical trials to date may not be indicative of results obtained in ongoing or future trials, the risk that adverse regulatory actions or other setbacks could occur in clinical trials even after promising results in earlier clinical trials or preclinical studies, the Company's ability to obtain regulatory approval for and commercialize its product candidates, LAVA's ability to identify any strategic alternatives or if so identified, be able to consummate any such transactions on terms acceptable to LAVA and its shareholders, and the risk that setbacks in development could occur as a result of the difficulty and uncertainty of pharmaceutical product development and other factors. There may be adverse effects on the Company's business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities, including between Russia and escalating tension in the Middle East. These and other risks are described in greater detail under the caption 'Risk Factors' in LAVA's most recent Annual Report on Form 20-F and other filings the Company makes with the Securities and Exchange Commission. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. CONTACTSInvestor Relationsir@ LifeSci Advisors (IR/Media)Joyce AllaireJallaire@
